House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Emergency medicine

Anaphylaxis: assessment and referral after emergency treatment

NICE · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG258 covers assessment, observation, referral and discharge after emergency treatment of suspected anaphylaxis. Its updated observation pathway starts from clinical resolution and varies with treatment response, severity, recurrence risk and access to help after discharge. It is an aftercare guideline, not a substitute for the acute resuscitation protocol.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Document the reaction and likely trigger

  • Record rapidly developing airway, breathing or circulatory compromise, with skin or mucosal changes when present. Severe anaphylaxis may occur without typical skin findings or shock; their absence does not define a mild reaction. [1]
  • Record symptom-onset time and the circumstances immediately preceding the episode to help identify a possible trigger. Keep the diagnosis as suspected anaphylaxis pending specialist assessment. [1]

Collect timed samples without displacing emergency treatment

  • In adults and young people aged 16 or older, take mast-cell tryptase as soon as possible after emergency treatment has begun, then a second sample ideally 1 to 2 hours after symptom onset and no later than 4 hours. [1]
  • In children younger than 16, consider the same timed sampling when venom, a drug or an idiopathic cause is suspected: first after emergency treatment starts, then ideally at 1 to 2 hours and no later than 4 hours from symptom onset. This is a consideration for the stated causes, not an indiscriminate requirement for every child. [1]
  • Explain that follow-up with the allergy service may require another blood sample to establish baseline tryptase. Acute samples and baseline assessment have distinct roles in the subsequent investigation. [1]

Use the complete risk-based observation criteria

  • A suitably qualified, experienced clinician may consider discharge after 2 hours, measured from resolved airway swelling, normal breathing and stable blood pressure and heart rate, only when all listed conditions are met: a good response within 5 to 10 minutes to a single IM adrenaline dose given within 30 minutes of onset; complete symptom resolution; possession of 2 in-date auto-injectors with knowledge of use; and appropriate adult supervision after discharge if needed. [1]
  • Observe for at least 6 hours after all symptoms resolve if treatment required 2 IM adrenaline doses or there is a history of a biphasic reaction. These are alternatives, either of which triggers the longer observation period. [1]
  • Observe for at least 12 hours after all symptoms resolve if any listed higher-risk feature is present: more than 2 adrenaline doses; severe asthma or severe respiratory compromise; possible ongoing allergen absorption; out-of-hours presentation; inability to respond to deterioration; or difficult geographical access to emergency care. [1]
  • After anaphylaxis during a supervised allergy challenge, a suitably qualified and experienced clinician may consider discharge after 2 hours from resolution even if 2 IM adrenaline doses were required. This is a specific supervised-challenge exception. [1]
  • Admit children and young people under 16 to an inpatient pediatric medical team if they cannot be discharged under the early-discharge criteria in recommendation 1.1.7. [1]

Arrange specialist investigation and ongoing care

  • After emergency treatment for suspected anaphylaxis, offer referral to a specialist allergy service, age-appropriate where possible. The service should be able to investigate and diagnose the cause, monitor and manage the condition, and educate the patient; separate adult and child referral pathways should be available. [1]

Prepare the patient and carers for another reaction

  • Before discharge, explain anaphylaxis symptoms, the possibility of a biphasic reaction, avoidance of a known suspected trigger and the allergy-referral process. Provide information about support groups and what to do if symptoms recur: use the auto-injector and call emergency services. [1]
  • Demonstrate the specific auto-injector brand and when to use it. Advise lying down afterwards, or sitting up if struggling to breathe, and avoiding standing or sudden position changes even if the person feels better. [1]
  • At discharge, ensure the patient has 2 in-date adrenaline auto-injectors and knows when and how to use them, prescribing them if necessary, unless the reaction was due to an easily avoidable drug allergy. Advise carrying the injectors at all times. [1]

Limitations and use

  • This guideline addresses assessment and referral after emergency care; it does not provide adrenaline dosing, fluid resuscitation or refractory-anaphylaxis treatment.
  • Observation periods are measured from the specified clinical resolution, not automatically from the first adrenaline dose or arrival time. All conditions and exceptions in the relevant pathway must be checked.
  • The supervised-allergy-challenge exception is a specialist judgment and should not be generalized to unsupervised community reactions.
  • Referral arrangements and auto-injector access require adaptation to local services, including availability in India.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Anaphylaxis: assessment and referral after emergency treatment

    Selected recommendation material consulted

Clinical practice guideline

Publication details

Issuing organisation
NICE
First published
27 May 2026
Resource type
Clinical practice guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Document the reaction and likely trigger
  • Collect timed samples without displacing emergency treatment
  • Use the complete risk-based observation criteria
  • Arrange specialist investigation and ongoing care
  • Prepare the patient and carers for another reaction
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House